Acta Neurologica Scandinavica · 1988 · 73 citations · 14 references
MedicineNeurologyRehabilitation MedicineMobility RehabilitationMovement DisordersNeurologic PharmacotherapyGait ImpairmentMobility AssessmentMultiple SclerosisMultiple Sclerosis PharmacotherapySpasticity ManagementSpasticity PharmacotherapyIsometric Muscle Strength TestingIsometric Strength TestingMultiple Sclerosis MobilityMultiple Sclerosis SpasticityMultiple Sclerosis TherapyMuscle SpasticityMuscle Weakness ProgressionTizanidine Therapy
Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study. No significant difference in efficacy was found. The most striking difference was seen in the side-effects: baclofen frequently caused more or less severe muscle weakness and even falling during walking and standing. Treatment with tizanidine produced an apparent improvement of mobility in some patients suffering from moderate or marked paresis associated with a marked spasticity of their legs. Isometric muscle strength did not show any significant changes during either treatment. The different impact of baclofen and tizanidine on mobility and weight support seems to be related to their different site of action in spasticity.
14
PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.
B Ashworth · PubMed · 1964 · 1.5K citations
Medicine, Neurology, Pharmacology +10
Rutger J. Ploeg, Harry Oosterhuis, Johan Reuvekamp · Journal of Neurology · 1984 · 177 citations
Baclofen, A New Antispastic Drug
Barry A. Sachais · Archives of Neurology · 1977 · 104 citations
Pharmacy, Neurology, Pharmacotherapy +15